| Autor: |
Michael Dörks, Kathrin Jobski, Stefan Herget‐Rosenthal, Falk Hoffmann, Antonios Douros |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Pharmacology Research & Perspectives, Vol 9, Iss 1, Pp n/a-n/a (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2052-1707 |
| DOI: |
10.1002/prp2.707 |
| Popis: |
Abstract There are concerns by the United States Food and Drug Administration (FDA) regarding a potential link between tyrosine kinase inhibitors targeting vascular endothelial growth factor (VEGF‐TKIs) and the risk of aortic dissection. Elevation of blood pressure induced by VEGF‐TKIs has been discussed as part of the pathomechanism. To address this important safety issue, we conducted a large pharmacovigilance study assessing the risk of aortic dissection reporting associated with the use of VEGF‐TKIs, thereby exploring the role of blood pressure. We queried the FDA Adverse Event Reporting System from 2004 to 2019 for reports including VEGF‐TKIs and aortic dissection and estimated reporting odds ratios (RORs) and 95% confidence intervals (CIs) of aortic dissection associated with the use of VEGF‐TKIs. Secondary analyses stratified by the strength of blood pressure elevation (≥10 mmHg vs. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
